8-K: Accuray Amends Financing, Cuts Workforce, Targets $25M Profit Boost

Accuray Incorporated announced amendments to its financing agreement, a 15% global workforce reduction, and a strategic transformation plan targeting $25 million in annualized operating profit improvement.

Summary

• Accuray Incorporated entered into Amendment No. 1 (December 12, 2025) and Amendment No. 2 (December 15, 2025) to its Financing Agreement, dated June 6, 2025.
• Amendment No. 1 allows for the inclusion of certain restricted cash in Liquidity calculations and extends the time for compliance with passive company requirements.
• Amendment No. 2 removed the leverage condition for drawing on the delayed draw term loan facility (DDTL), reduced DDTL commitments to $18.25 million, and delayed the commencement of testing total leverage ratio and fixed charge coverage ratio financial covenants until the fiscal quarter ending December 31, 2026.
• The Second Amendment also increased the prepayment premium, required Accuray to pay additional premiums totaling $1.9 million, and reduced amounts available under the revolving credit facility by $5 million through December 31, 2026.
• Concurrently with the Second Amendment, Accuray issued warrants to certain lenders to purchase 3,062,726 shares (Super Premium, $1.50 exercise), 2,187,661 shares (Premium, $1.25 exercise), and 1,750,129 shares (Penny, $0.01 exercise), all expiring December 15, 2032.
• Additional warrants will be issued upon drawing on the DDTL, with varying exercise prices and based on a percentage of fully diluted shares.
• The company initiated an organizational realignment on December 15, 2025, as the first phase of its transformation plan, resulting in the elimination of approximately 15% of its global workforce.
• Total restructuring costs are estimated at approximately $11 million, with $5.4 million for headcount reductions and $5.6 million for other transformation elements, mostly cash, expected to be recorded in fiscal 2026 Q2, Q3, and Q4.
• This first phase of the transformation plan is expected to improve operating profitability by approximately $25 million on an annualized, run-rate basis, with about $12 million of this realized in fiscal year 2026.
• Accuray maintains its forecasts for full year fiscal 2026.

Sentiment

Score: 6

Explanation: The filing presents a mixed but strategically positive outlook. While there are immediate negatives like workforce reductions, increased premiums, and reduced credit availability, these are framed as necessary steps for a transformation plan expected to yield significant annualized operating profit improvement ($25 million). The company maintaining its full-year forecasts and lender support suggests a controlled, forward-looking strategy, but the immediate costs and dilution are notable.

Positives

• The first phase of the transformation plan is expected to improve operating profitability by approximately $25 million on an annualized, run-rate basis.
• Approximately $12 million of the expected operating profit improvement is anticipated to be realized in fiscal year 2026.
• The transformation plan aims to enhance competitiveness, drive sales growth, and set the stage for renewed growth.
• Strategic lending partner TCW supports the company's strategic decisions, believing they strengthen the foundation for future growth and margin expansion.
• The company maintains its forecasts for full year fiscal 2026, suggesting confidence in its overall financial trajectory despite the restructuring.

Negatives

• The company agreed to pay additional premiums totaling $1.9 million in connection with the Second Amendment to the Financing Agreement.
• The prepayment premium applicable to certain prepayments was increased.
• Amounts available to be drawn under the revolving credit facility were reduced by $5 million through December 31, 2026.
• The company issued warrants to lenders, which could lead to dilution for existing shareholders if exercised.
• A reduction of approximately 15% of the company's global workforce was initiated, impacting employees.
• Total restructuring charges are estimated at approximately $11 million, substantially all of which will be paid in cash, impacting short-term financials.

Risks

• The company's ability to execute upon its transformation plan and realize the expected benefits.
• The effect of the global macroeconomic environment on the operations of the company and its customers and suppliers.
• Disruptions to the company's supply chain, including increased logistics costs.
• The company's ability to achieve widespread market acceptance of its products.
• Substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt.
• The effect of enhanced international tariffs on the company.
• The company's ability to realize the expected benefits of the China joint venture and other partnerships.
• Risks inherent in international operations.
• The company's ability to maintain or increase its gross margins on product sales and services.
• Delays in regulatory approvals or the development or release of new offerings.
• The company's ability to meet the covenants under its credit facilities.
• The company's ability to convert backlog to revenue.
• Risks ordinarily incident to workforce reductions.

Future Outlook

The company expects its first phase of the transformation plan to improve operating profitability by approximately $25 million on an annualized, run-rate basis, with about $12 million of this realized in fiscal year 2026. It anticipates virtually all initiatives to be fully implemented by fiscal 2026 year-end. Accuray maintains its forecasts for full year fiscal 2026 and plans to provide further updates on its transformation plan as material developments occur.

Management Comments

• "As a team, we are laser focused on a clear corporate, product and service strategy, and the phase one initiatives, which have been driven by the transformation leaders we announced at the time of our first fiscal quarter earnings release, are designed to set the stage for that strategy."
• "The changes sharpen our focus on sales and service in every region around the world, establish a faster, more efficient operating rhythm, and create an efficient, higher-margin cost structure."
• "All of these initiatives will increase our competitiveness, ensure our teams are poised to deliver growth in each market, and, frankly, make us a better company."
• "At the same time, our commitment to innovation, quality, reliability, customer satisfaction, and patient care remains paramount."
• "By simplifying our structure, strengthening accountability, and aligning resources with the areas of greatest strategic impact, we are better positioned to continue delivering exceptional value to patients, providers, employees, and shareholders."

Industry Context

The announcement reflects a broader industry trend where companies in the medical device and healthcare technology sectors are undergoing strategic realignments and cost optimization efforts to enhance competitiveness, improve operational efficiency, and drive profitability in a dynamic market. Accuray's focus on streamlining commercial structures, centralizing core functions, and reallocating engineering resources aligns with strategies employed by peers to adapt to evolving market demands and technological advancements in radiation therapy. The support from its strategic lending partner, TCW, also indicates a belief in the long-term viability and strategic positioning of Accuray within its niche.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance and future exercise of warrants. Short-term financial impact from restructuring charges. Long-term potential for increased operating profitability and renewed growth.
• Employees: Approximately 15% of the global workforce will be eliminated, leading to job losses for affected individuals. Remaining employees may experience changes in roles, reporting structures, and increased workload during the transition.
• Lenders: Received warrants as an inducement for the financing agreement amendments, potentially increasing their return.
• Customers/Providers: The company states its commitment to innovation, quality, reliability, customer satisfaction, and patient care remains paramount, aiming to deliver exceptional value. The transformation is intended to enhance competitiveness and service.

Next Steps

• Most affected employees are expected to exit the company by the end of the third quarter of fiscal 2026.
• Restructuring charges are expected to be recorded in the second, third, and fourth quarters of fiscal year 2026.
• Virtually all transformation initiatives are expected to be fully implemented by fiscal 2026 year-end.
• The company expects to give further updates concerning its transformation plan from time to time as material developments occur.
• Copies of the First Amendment, Second Amendment, and various warrant forms will be filed as exhibits to the company's Quarterly Report on Form 10-Q for the quarter ending December 31, 2025.

Key Dates

Recommendation

The filing presents a strategic pivot with both immediate costs and significant potential long-term benefits. The workforce reduction and restructuring charges are negative in the short term, and the issuance of warrants introduces potential dilution. However, the projected $25 million annualized operating profit improvement and the company's reaffirmation of its full-year fiscal 2026 forecasts suggest management is confident in the plan's ability to stabilize and improve the company's financial health. The support from the strategic lending partner also provides a degree of confidence. Given the mixed signals—short-term pain for long-term gain—a "hold" recommendation is appropriate for investors to observe the execution of the transformation plan and its impact on future financial results before making a more definitive move. The delay in covenant testing also provides some breathing room, but the increased premiums and reduced credit facility are cautionary.

Keywords

Accuray, ARAY, financing agreement, debt, warrants, equity, workforce reduction, restructuring, transformation plan, operating profitability, cost savings, medical devices, radiation therapy, oncology, neuro-radiosurgery